Michael Meyers

Michael currently is the Senior Vice President and Chief Medical Officer at Syndax Pharmaceuticals, where he has served since 2015. Prior to joining Syndax, he held a number of senior R&D roles at Johnson & Johnson, including serving as Vice President, GU Oncology, Compound and Clinical Leader, and as Vice President, Oncology Scientific Innovation in Johnson and Johnson’s London Innovation Centre. Michael also led the U.S. Oncology Medical Affairs team at Aventis Pharmaceuticals Inc and worked in oncology clinical development at the Schering-Plough Research Institute. Prior, he was on the Memorial Sloan Kettering Cancer Center faculty, specializing in Clinical Immunology and melanoma. He received his MD and his PhD in Microbiology and Immunology from Albert Einstein College of Medicine in New York and was elected to Alpha Omega Alpha (the medical school honor society). He completed his residency in Internal Medicine at Columbia Presbyterian Medical Center and his fellowship, where he served as Chief Fellow in Medical Oncology, at Memorial Sloan Kettering Cancer Center.